Background Alteplase is effective for treatment of acute ischaemic stroke but debate continues
about its use after longer times since stroke onset, in older patients, and among patients …

… 71 Muir KW, Lees KR. Initial experience with remacemide hydrochloride in patients with
acute ischaemic stroke. In: Proceedings of the 2nd International Conference on Neuroprotective …

Background and Purpose— A perceived weakness of the modified Rankin Scale is potential
for interobserver variability. We undertook a systematic review of modified Rankin Scale …

Background Intravenous thrombolysis with alteplase is the only approved treatment for acute
ischemic stroke, but its efficacy and safety when administered more than 3 hours after the …

… Prof Kennedy R Lees, FRCP Kennedy R Lees … Correspondence to: Prof Kennedy R Lees,
University Department of Medicine and Therapeutics, Gardiner Institute, Western Infirmary, …

… In the UK, source data verification was done by independent clinical staff under the direction
of KR Lees and GA Ford. Boehringer Ingelheim was responsible for reporting of serious …

Objective: To examine the association between patent foramen ovale (PFO) and atrial septal
aneurysm (ASA) and stroke. Method:— Data from case-control studies that examined the …

Background and Purpose— Most acute ischemic stroke patients arrive after the 3-hour time
window for recombinant tissue plasminogen activator (rtPA) administration. The …

Background— Evidence for efficacy of dual antiplatelet therapy in stroke is limited.
Symptomatic carotid stenosis patients are at high risk of early recurrent stroke. In this group, …

Background Intravenous alteplase is approved for use within 3 h of ischaemic stroke onset,
although a meta-analysis of randomised controlled trials suggests treatment benefit up to 4·5 …